HUTCHMED (NASDAQ:HCM) Sees Strong Trading Volume – Still a Buy?

HUTCHMED (China) Limited (NASDAQ:HCM) saw unusually-strong trading volume on Monday . Approximately 71,022 shares were traded during trading, an increase of 3% from the previous session’s volume of 69,081 shares.The stock last traded at $16.03 and had previously closed at $14.99.

Analyst Ratings Changes

Separately, StockNews.com downgraded shares of HUTCHMED from a “buy” rating to a “hold” rating in a report on Monday, November 18th.

HUTCHMED Price Performance

The company’s 50 day moving average price is $16.69 and its 200 day moving average price is $17.86. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of HCM. Rhumbline Advisers raised its position in shares of HUTCHMED by 8.1% in the second quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock valued at $129,000 after buying an additional 564 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of HUTCHMED by 74.8% during the 2nd quarter. Renaissance Technologies LLC now owns 131,300 shares of the company’s stock valued at $2,248,000 after buying an additional 56,200 shares during the period. Vanguard Personalized Indexing Management LLC grew its position in HUTCHMED by 9.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,216 shares of the company’s stock worth $226,000 after acquiring an additional 1,168 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in HUTCHMED during the second quarter worth $213,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of HUTCHMED in the 2nd quarter valued at approximately $279,000. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.